Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
1998-10-01
2001-06-12
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S177000
Reexamination Certificate
active
06245757
ABSTRACT:
BACKGROUND OF THE INVENTION
Oxygen is supplied to the cells by the blood and most cellular energy production is tightly coupled to oxygen. Whenever the blood flow to an organ is interrupted, a state of ischemia exists. During ischemia, cellular ATP will be consumed and usually cannot adequately be replenished in the absence of a supply of oxygen. Ischemia can exist for only a portion of an organ when the blockage of the blood supply to the organ is not total. In addition to total ischemia, or no blood flow, there are intermediate degrees of ischemia.
Significant ischemia occurs in stroke and during most cases of open heart surgery, all episodes of coronary occlusion or heart attack, all cases of organ transplantation, certain procedures such as liver shunt operations and a variety of other situations in which either significant stress or a period of shock has compromised the functioning of one or more organs of the body. In all of these situations, cellular energy metabolism is impaired, and its restoration is critical to the recovery of organ function.
For example, stroke, or cerebrovascular disease, is the name for several disorders that occur within seconds or minutes after the blood supply to the brain is disturbed. Stroke is the third leading cause of death in developed countries. Approximately 550,000 Americans suffer a stroke each year; one fourth of them die and half of the survivors have residual disabilities, including paralysis of face or extremities, speech disorders, loss of bladder function, inability to swallow or dementia. Stroke is the principal cause of severe disability, often requiring institutionalization of stroke survivors at a total cost in the U.S. of $20 to 30 billion dollars per year. Stroke is more likely to occur in the elderly, and the risk doubles each decade after age 35 years. Five percent of the population older than 65 years has had a stroke.
Symptoms of stroke may progress or fluctuate during the first day or two after onset; this is called evolution. When no further deterioration occurs, the condition is considered to be a completed stroke. The only warning signal that suggests susceptibility to a stroke is a transient ischemic attack (TIA).
Strokes are characterized by the location and type of disturbance. The most common is a deficient supply of blood through an artery (ischemia). About 84% of strokes (about 400,000 per year in the U.S.) result from occlusion of cerebral arteries by blood clots. Ischemic cell damage follows rapidly upon interruption of the blood supply downstream from the clot. The remaining 16% of strokes are the result of intracerebral or subarachnoid hemorrhage. While hemorrhage induces other injurious events, ischemia resulting from the “short circuited” blood flow is still a significant factor in neuronal damage from hemorrhagic strokes.
Cell death occurs rapidly in the core region of a stroke, where blood flow is reduced to about 20% of normal. However, there is a larger area of potential injury, called the ischemic penumbra, where blood flow is reduced to a lesser extent. Cells in this region are endangered, but may not be irreversibly damaged. It is this penumbral area wherein neuroprotective agents may have their most beneficial effects in preventing cell damage and death due to ischemia and thereby reducing the incidence of long term disabilities.
Pharmacological intervention into the stroke process has not been successful. For example, studies evaluating the effectiveness of corticosteroids in the setting of head injury or global or focal brain ischemia have demonstrated either no improvement or a worsening of neurological outcome. See, for example, C. T. Wass et al.,
Anesthesiology,
84, 644 (1996) and references cited therein. A study of stroke patients treated primarily with dexamethasone or methylprednisolone showed no significant difference in outcome between steroid and non-steroid treated patients. J. DeReuck et al.,
Eur. Neurol.,
28, 70 (1988).
Due to the lack of available pharmacotherapeutic agents, a significant percentage of the population subject to stroke or its after effects are poorly managed. None of the drugs presently available are capable of preventing damage due to stroke and most, such as anticoagulants, which can be shown to speed clot dissolution and hasten reperfusion if given within three hours of the onset of ischemia, have disturbing side effects. Anticoagulants can in fact be fatal if used inappropriately, e.g., for treating a hemorrhagic stroke. Clearly, current therapy has failed to “seize control” of this debilitating pathology.
Therefore, an object of this invention is to provide pharmaceutical agents useful in the treatment of stroke.
A further object of this invention is to provide a method of treating stroke and related ischemic disorders.
SUMMARY OF THE INVENTION
The present invention provides a method to treat cell damage due to ischemia, as caused by stroke or infarct comprising administering to a mammal afflicted with ischemic cell damage, an effective amount of a pharmaceutical composition comprising a progestin in combination with a pharmaceutically acceptable liquid delivery vehicle, following onset of ischemia. The amount of progestin is effective to ameliorate or mitigate at least one of the effects of ischemia, such as the acute phase of stroke, myocardial or pulmonary infarction or their aftereffects, such as those described hereinabove. It is believed that the present method functions, at least in part, by the ability of the progestin to reduce the damage caused by ischemia, i.e., the brain damage caused by cerebral ischemia, and its aftereffects. The efficacy of the present method may also be due to enhancement of the ability of the brain to recognize after damage, by enhancing its intrinsic ability to compensate for injury.
As used herein the term “progestin” or “progestogen” includes the steroid hormones disclosed under that designation in
Remington's Pharmaceutical Sciences
, A. R. Gennaro, ed., Mack Publishing Co. (18th ed. 1990) at pages 990-993, as well as their derivatives and bioactive metabolites. A preferred progestin for use in the present method is progesterone (pregn-4-ene-3,20-dione), its metabolites such as 5-dehydroprogesterone and allopregnanolone, and related compounds such as 5-pregnane-3,20-dione.
In order for a product to have utility in treating cell damage due to ischemia from conditions such as stroke, the product must provide a “clinical improvement” to the host when administered after the ischemic event has occurred. Functional outcome is the primary endpoint used by the FDA to evaluate therapeutic interventions for stroke. For the stroke patient a number of scales, including the Barthel index and the NIH stroke scale are employed as primary outcome measures. The critical endpoint for any effective therapy for stroke is improvement of neurologic function. Therefore, a successful therapeutic intervention in an experimental stroke model must reduce neurologic deficits. The present invention demonstrates for the first time that a progestin can be administered to a mammal after the onset of an ischemic event and significantly improve clinically relevant end points or physiological conditions such as neurological function and weight loss, compared to mammals not receiving the treatment.
Progesterone has been used in previous studies involving models of ischemia; however the progesterone was delivered prior to the onset of the occlusion and no improvement was seen in clinically relevant physiological conditions. Progesterone administered to rats one hour prior to middle cerebral artery occlusion was reported by A. L. Betz et al.,
Stroke
, 21, 1199 (1990) to reduce brain edema in the early stages of ischemia. In the Betz work, focal ischemia was induced following extensive surgical intervention, including craniotomy to expose the brain. Such extensive surgical manipulation alone is sufficient to induce severe edema, apart from any edema attributable to the ischemia. This fact was noted in the report, where it was stated that control a
Chopp Michael
Jiang Ning
Fay Zohreh
Research Corporation Technologies Inc.
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Use of progestins to treat ischemic event does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of progestins to treat ischemic event, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of progestins to treat ischemic event will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2472660